Marshall Wace, LLP Supernus Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 51,139 shares of SUPN stock, worth $1.82 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

51,139

Previous 73,519 30.44%

Holding current value

$1.82 Million

Previous $1.97 Million 18.92%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $576,732 - $786,880	-22,380 Reduced 30.44%	51,139 $1.59 Million
Q2 2024 Aug 14, 2024	BUY	$25.99 - $33.85 $1.91 Million - $2.49 Million	73,519 New	73,519 $1.97 Million
Q1 2022 May 16, 2022	SELL	$28.51 - $32.9 $1.66 Million - $1.91 Million	-58,078 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$26.37 - $34.22 $434,419 - $563,740	-16,474 Reduced 22.1%	58,078 $1.7 Million
Q2 2021 Aug 13, 2021	SELL	$26.72 - $33.19 $1.18 Million - $1.46 Million	-44,057 Reduced 37.14%	74,552 $2.3 Million
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $422,625 - $550,375	17,500 Added 17.31%	118,609 $3.11 Million
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $1.17 Million - $1.7 Million	-66,028 Reduced 39.51%	101,109 $2.54 Million
Q3 2020 Nov 16, 2020	SELL	$20.2 - $25.05 $5.13 Million - $6.36 Million	-253,963 Reduced 60.31%	167,137 $3.48 Million
Q2 2020 Aug 13, 2020	BUY	$17.09 - $24.89 $2.39 Million - $3.48 Million	139,931 Added 49.77%	421,100 $10 Million
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $556,238 - $950,416	-38,494 Reduced 12.04%	281,169 $5.06 Million
Q4 2019 Feb 14, 2020	SELL	$19.93 - $29.13 $6.3 Million - $9.21 Million	-316,085 Reduced 49.72%	319,663 $7.58 Million
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $1.96 Million - $2.57 Million	77,045 Added 13.79%	635,748 $17.5 Million
Q2 2019 Aug 14, 2019	SELL	$29.96 - $38.87 $2.22 Million - $2.88 Million	-74,027 Reduced 11.7%	558,703 $18.5 Million
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $6.84 Million - $8.77 Million	208,766 Added 49.24%	632,730 $22.2 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $12.9 Million - $20.7 Million	418,904 Added 8278.74%	423,964 $14.1 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $216,062 - $286,143	5,060 New	5,060 $255,000

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

61.1M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.9B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Supernus Pharmaceuticals, Inc. Transaction History